AMENDMENT TO THE CLAIMS

1-36. Canceled

37. (Previously Presented) A method for reducing tissue factor levels to treat cancer comprising administering to the mammal a therapeutically effective amount of an antibody capable of binding native human tissue factor, wherein the method further comprises contacting cancer cells expressing TF with the antibody or fragment to reduce the tissue factor levels in the mammal to treat the cancer.

38. (Previously Presented) The method of claim 37, wherein Factor X (FX) or Factor VII/VIIa (FVII/FVIIa) binding to the complex is inhibited.

39. (Previously Presented) The method of claim 37, wherein the antibody or fragment has the binding specificity for native human tissue factor about equal to or greater than H36.D2.B7 [ATCC HB12255].

40. (Previously Presented) The method of claim 38, wherein the antibody has identifying characteristics of H36.D2.B7 [ATCC HB-12255].

41. (Previously Presented) The method of claim 40, wherein the antibody is H36.D2.B7 [ATCC HB- 12255].

42. (Previously Presented) The method of claim 37, wherein the antibody is a monoclonal antibody.

43. (Previously Presented) The method of claim 42, wherein the antibody is chimeric or humanized.

44. (Previously Presented) The method of claim 43, wherein the antibody is chimeric and comprises a constant region of human origin.

45. (Previously Presented) The method of claim 43, wherein the humanized antibody comprises hypervariable regions of non-human origin.

46. (Previously Presented) The method of claim 37, wherein the antibody is a single chain antibody.

47. (Previously Presented) The method of claim 37, wherein the antibody comprises a sequence that has at least about 70 percent sequence identity to SEQ ID NO: 1.

48. (Currently Amended) The method of claim 47, wherein the antibody comprises a sequence represented by ~~SEQ ID NO:2 or~~ SEQ ID NO:4.

49. (Previously Presented) The method of c laim 48, wherein the antibody comprises hypervariable regions that have at least 90 percent sequence identity to SEQ ID NOS. 5 through 10 inclusive.

50. (Previously Presented) The method of claim 49, wherein the antibody comprises hypervariable regions represented by SEQ ID NOS. 5 through 10 inclusive.

51. (Previously Presented) The method of claim 37, wherein the antibody comprises an immunological effector molecule.

52. (Previously Presented) The method of claim 51, wherein the immunological effector molecule is IgG1 or IgG3.

53. (Previously Presented) The method of claim 37, wherein the antibody is an immunologically active antibody fragment.

54. (Previously Presented) The method of claim 53, wherein the fragment is Fab, F(v), Fab' or F(ab)2.

55. (Previously Presented) The method of claim 37, wherein the FX or FVII/FVIIa binding to the complex is inhibited by at least 80 percent in a standard in vitro binding assay.

56. (Previously Presented) The method of claim 37, wherein the FX or FVII/FVIIa binding to the complex is inhibited by at least 90 percent in a standard in vitro binding assay.

57. (Previously Presented) The method of claim 37, wherein the FX or FVII/FVIIa binding to the complex is inhibited by at least 95 percent in a standard in vitro binding assay.

58. (Previously Presented) The method of claim 37, wherein administration of the antibody increases the clotting time by at least 90 percent according to a prothrombin time (PT) assay.

59. (Previously Presented) The method of claim 37, wherein administration of the antibody increases the clotting time by at least 150 percent according to a prothrombin time (PT) assay.

60. (Previously Presented) The method of claim 37, wherein administration of the antibody increases the clotting time by at least 300 percent according to a prothrombin time (PT) assay.

61. (Previously Presented) The method of claim 37, wherein the cancer cell is a pancreatic, ovarian or small lung cell carcinoma.

62. (Withdrawn) A method for detecting cancer cells that express TF, the method comprising contacting cancer cells expressing TF with a detectably-labeled antibody capable of binding native human tissue factor to form an immune complex; and detecting the immune complex as being indicative of the cancer cells that express the TF.

63. (Withdrawn) The method of claim 62, wherein the method further comprises administering an effective amount of the antibody to a mammal and detecting the cancer cells that express the TF in the mammal.

64. (Withdrawn) The method of claim 62, wherein the method further comprises isolating a biological sample from the mammal and detecting the cancer cells that express TF in the sample.